Foghorn Therapeutics Strengthens Board With Addition Of Dr. Neil Gallagher And Stuart Duty

Foghorn® Therapeutics Inc., a clinical-stage biotech company focused on developing therapies that correct abnormal gene expression, has announced the election of two new members to its Board of Directors: Neil Gallagher, M.D., Ph.D., and Stuart Duty.

“Neil and Stuart are experienced leaders with decades of deep and multifaceted understanding of the biotechnology industry. We are pleased to welcome them to our Board of Directors and will leverage their strategic insights as we further advance our pipeline,” said Adrian Gottschalk, President and Chief Executive Officer of Foghorn.

Dr. Gallagher brings extensive clinical development and regulatory experience, having held leadership roles in global pharmaceutical companies. His scientific background and drug development expertise will contribute valuable insights as Foghorn advances its novel pipeline.

Dr. Gallagher stated, “Foghorn is poised to successfully develop multiple highly selective therapies against challenging targets implicated in different cancers. I look forward to working with the Board of Directors and the management team to help shape the Foghorn pipeline, which has the strong potential to address unmet needs and change treatment paradigms for multiple types of cancers.”

Stuart Duty adds strategic and financial depth to the board, with a strong background in investment banking and biotech corporate development. Both appointees are expected to support Foghorn’s mission to transform patient care through innovative epigenetic-based therapies.

Mr. Duty added, “I am impressed with Foghorn’s sophisticated and proven small molecule development capabilities and, particularly, their leadership in pioneering selective protein degradation. I am excited to join the Board of Directors at this important time and help maximise Foghorn’s clinical and preclinical pipeline.”